StockData
BridgeBio Oncology Therapeutics, Inc. logo

BridgeBio Oncology Therapeutics, Inc. (BBOT) stock

BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.80−0.14 (-6.96%)

Close on Nov 18, 2026Market cap $144.72MP/E –Yield –

BridgeBio Oncology Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

BridgeBio Oncology Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$151.56M. For fiscal 2025 it was -$114.50M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$114.50M–
FY2024Dec 31, 2024-$55.08M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$44.41M–
Q1 FY2026Mar 31, 2026-$35.94M–
Q4 FY2025Dec 31, 2025-$42.31M–
Q3 FY2025Sep 30, 2025-$28.91M–
Q2 FY2025Jun 30, 2025-$23.52M–
Q1 FY2025Mar 31, 2025-$19.76M–
Q4 FY2024Dec 31, 2024-$15.05M–

More BridgeBio Oncology Therapeutics figures

See a number that looks wrong?